Page last updated: 2024-10-25

clonidine and Syndrome

clonidine has been researched along with Syndrome in 43 studies

Clonidine: An imidazoline sympatholytic agent that stimulates ALPHA-2 ADRENERGIC RECEPTORS and central IMIDAZOLINE RECEPTORS. It is commonly used in the management of HYPERTENSION.
clonidine (amino form) : A clonidine that is 4,5-dihydro-1H-imidazol-2-amine in which one of the amino hydrogens is replaced by a 2,6-dichlorophenyl group.

Syndrome: A characteristic symptom complex.

Research Excerpts

ExcerptRelevanceReference
" Now, we sought to determine if we could detect a GH response to hypoglycemia (ITT: insulin tolerance test) or clonidine (CL) in these patients."9.12GH response to hypoglycemia and clonidine in the GH-releasing hormone resistance syndrome. ( Aguiar-Oliveira, MH; Almeida, JC; Britto, AV; Farias, CT; Oliveira, CR; Oliveira, JL; Parmigiani, G; Prado, CM; Salvatori, R; Serpa, MG; Vicente, TA, 2006)
"We report a rare case of Shapiro's syndrome variantrevealed by episodes of headache with spontaneous hypothermia witheffectiveness of clonidine therapy in a 76-year-old Parkinson's disease woman."8.02Episodic headache with spontaneous hypothermia reveal Shapiro's syndrome variant with effectiveness of clonidine therapy. ( Andriuta, D; Aubignat, M; Krystkowiak, P; Tir, M, 2021)
" The mother took clonidine during pregnancy."7.66Roberts's syndrome and clonidine. ( Beshara, D; Levy, JM; Stoll, C, 1979)
"Clonidine was safe to administer and should be considered early when treating IS."5.72Use of clonidine in the treatment of Irukandji syndrome: A 4-year retrospective cohort study on safety, efficacy and clinical utility. ( Isman, A; Little, M; Seymour, J, 2022)
"Clonidine therapy was also associated with a return to normal central temperature regulation."5.28Clonidine therapy for Shapiro's syndrome. ( Anderson, JA; Edwards, CR; Walker, BR, 1992)
" Now, we sought to determine if we could detect a GH response to hypoglycemia (ITT: insulin tolerance test) or clonidine (CL) in these patients."5.12GH response to hypoglycemia and clonidine in the GH-releasing hormone resistance syndrome. ( Aguiar-Oliveira, MH; Almeida, JC; Britto, AV; Farias, CT; Oliveira, CR; Oliveira, JL; Parmigiani, G; Prado, CM; Salvatori, R; Serpa, MG; Vicente, TA, 2006)
"Six subjects with the phobic-anxiety syndrome were treated in a controlled, crossover trial of clonidine hydrochloride v imipramine hydrochloride for periods of four weeks each."5.05Panic-induced elevation of plasma MHPG levels in phobic-anxious patients. Effects of clonidine and imipramine. ( Elsworth, JD; Ko, GN; Leigh, H; Redmond, DE; Rifkin, BG; Roth, RH, 1983)
"The paper considers mechanisms of action and clinical efficacy of the drug sirdalud (tizanidine) in painful musculotonic syndromes."4.79[The use of sirdalud in painful muscle tonic syndromes]. ( Damulin, IV, 1997)
"We report a rare case of Shapiro's syndrome variantrevealed by episodes of headache with spontaneous hypothermia witheffectiveness of clonidine therapy in a 76-year-old Parkinson's disease woman."4.02Episodic headache with spontaneous hypothermia reveal Shapiro's syndrome variant with effectiveness of clonidine therapy. ( Andriuta, D; Aubignat, M; Krystkowiak, P; Tir, M, 2021)
" All the patients had excessive pressor and tachycardia responses to the mental-arithmetic and cold pressor tests and marked hypersensitivity to clonidine."3.68The diagnosis and treatment of baroreflex failure. ( Biaggioni, I; Hollister, AS; Mosqueda-Garcia, R; Netterville, JL; Robertson, D; Robertson, RM, 1993)
"15 mg clonidine (Catapresan) in 11 patients (averaged age 60 years) with symptomatic bradycardia (dizzy spells, syncope, palpitations)."3.66[Clinidine-induced bradycardia: studies of the effect on the human sinus node (author's transl)]. ( Horn, H; Neuss, H; Schlepper, M; Thormann, J, 1981)
" The mother took clonidine during pregnancy."3.66Roberts's syndrome and clonidine. ( Beshara, D; Levy, JM; Stoll, C, 1979)
" Advantages, potential side effects, and dosing for multiple modes of delivery are discussed."2.43Long-term use of clonidine in a critically-ill infant. ( Lowery, R; Polaner, DM; Zuk, J, 2005)
"Pheochromocytomas are catecholamine-producing tumors, representing one of the most important causes of secondary hypertension."2.40[Clinical and endocrine diagnosis of pheochromocytoma]. ( Kopf, D; Lehnert, H; Mundschenk, J; Schulz, C, 1997)
"Clonidine was safe to administer and should be considered early when treating IS."1.72Use of clonidine in the treatment of Irukandji syndrome: A 4-year retrospective cohort study on safety, efficacy and clinical utility. ( Isman, A; Little, M; Seymour, J, 2022)
"The numb chin syndrome is a rare manifestation of intractable pain in the palliative care setting and represents a major therapeutic challenge."1.43Spontaneous Osteonecrosis of the Jaw During Bisphosphonate Therapy: An Unusual Etiology of the Numb Chin Syndrome. ( Bardelli, D; Fusi-Schmidhauser, T, 2016)
" There were no significant changes in the half-life (8."1.29Hormonal and metabolic effects and pharmacokinetics of recombinant insulin-like growth factor-I in growth hormone receptor deficiency/Laron syndrome. ( Cohen, P; Diamond, FB; Fielder, PJ; Gargosky, S; Guevara-Aguirre, J; Rosenbloom, AL; Rosenfeld, RG; Vaccarello, MA; Wilson, K, 1993)
"Clonidine therapy was also associated with a return to normal central temperature regulation."1.28Clonidine therapy for Shapiro's syndrome. ( Anderson, JA; Edwards, CR; Walker, BR, 1992)
"Clonidine therapy was associated with an initial dramatic decrease in the frequency of diaphoretic episodes as well as with a fall in NE release rate and increases in NE clearance and volume of distribution."1.28Altered norepinephrine metabolism in Shapiro's syndrome. ( Cahalan, DD; Forrester, JM; Halter, JB; Linares, OA; Rosen, SG; Sanfield, JA, 1989)

Research

Studies (43)

TimeframeStudies, this research(%)All Research%
pre-199016 (37.21)18.7374
1990's14 (32.56)18.2507
2000's7 (16.28)29.6817
2010's4 (9.30)24.3611
2020's2 (4.65)2.80

Authors

AuthorsStudies
Isman, A1
Seymour, J1
Little, M2
Aubignat, M1
Tir, M1
Krystkowiak, P1
Andriuta, D1
Duma, SN1
Fusi-Schmidhauser, T1
Bardelli, D1
Somerville, A1
Sriganesh, K1
Smita, V1
Aravind, HS1
Damulin, IV2
Silvani, P1
Camporesi, A1
Zoia, E1
Leoncino, S1
Salvo, I1
Lowery, R1
Zuk, J1
Polaner, DM1
Tobias, JD1
Vranken, JH1
van Kan, HJ1
van der Vegt, MH1
Salvatori, R1
Serpa, MG1
Parmigiani, G1
Britto, AV1
Oliveira, JL1
Oliveira, CR1
Prado, CM1
Farias, CT1
Almeida, JC1
Vicente, TA1
Aguiar-Oliveira, MH1
Hubbell, FA1
Weber, MA1
Houston, MC1
Piccione, E1
Sesti, F1
Manna, C1
Meinck, HM2
Ricker, K1
Conrad, B2
Ko, GN1
Elsworth, JD1
Roth, RH1
Rifkin, BG1
Leigh, H1
Redmond, DE1
Thormann, J1
Neuss, H1
Horn, H1
Schlepper, M1
Vaccarello, MA1
Diamond, FB1
Guevara-Aguirre, J1
Rosenbloom, AL1
Fielder, PJ1
Gargosky, S1
Cohen, P1
Wilson, K1
Rosenfeld, RG1
Hong, C1
Song, KY1
Wong, V1
Sobala, G1
Losowsky, M1
Wulf, H1
Gleim, M1
Mignat, C1
Reynisdottir, S1
Ellerfeldt, K1
Wahrenberg, H1
Lithell, H1
Arner, P1
Robertson, D1
Hollister, AS1
Biaggioni, I1
Netterville, JL1
Mosqueda-Garcia, R1
Robertson, RM1
McCracken, JT1
Martin, W1
Vorobeĭchik, IaM1
Kukushkin, ML1
Reshetniak, VK1
Ovechkin, AM1
Gnezdilov, AV1
Lehnert, H1
Schulz, C1
Mundschenk, J1
Kopf, D1
Burnstein, Y1
Shelton, K1
Higginbotham, EJ1
Mercadante, S1
Serretta, R1
Sapio, M1
Villari, P1
Calderone, L1
Ejaz, AA1
Meschia, JF1
Gordon, VM1
Opfer-Gehrking, TL1
Novak, V1
Low, PA1
Yudkin, JS1
Bruce, DL1
Croley, TF1
Lee, JS1
Stoll, C1
Levy, JM1
Beshara, D1
Walker, BR1
Anderson, JA1
Edwards, CR1
Galassi, AR1
Kaski, JC1
Pupita, G1
Vejar, M1
Crea, F1
Maseri, A1
Sato, T1
Igarashi, N1
Minami, S1
Okabe, T1
Hashimoto, H1
Hasui, M1
Kato, E1
Pranzatelli, MR1
Schultz, L1
Snodgrass, SR1
Sanfield, JA1
Linares, OA1
Cahalan, DD1
Forrester, JM1
Halter, JB1
Rosen, SG1
Lechin, F1
van der Dijs, B1
Jakubowicz, D1
Camero, RE1
Villa, S1
Arocha, L1
Lechin, AE1
Schneider, KW1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Double-Blinded, Placebo-Controlled Study To Assess Hemodynamic Changes, Orthostatic Tolerance, Out-Patient Fatigue And Quality Of Life In Neuropathic And Non-Neuropathic POTS Patients In Response To Adrenoreceptor Agonist And Antagonist[NCT03070730]Phase 1/Phase 28 participants (Actual)Interventional2011-08-15Terminated (stopped due to Recruitment was slow and subjects declined participation after signing the ICF.)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change in Blood Pressure From Baseline

(NCT03070730)
Timeframe: 1 week after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Blood Pressure From Baseline

(NCT03070730)
Timeframe: 1 week after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Blood Pressure From Baseline

(NCT03070730)
Timeframe: 1 week after third intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Fatigue Score on the Chalder Fatigue Questionnaire From Baseline

A 14 item self-report questionnaire. Subjects respond on a continuum of 1 to 4 questions evaluating fatigue intensity while distinguishing physical from mental fatigue. (NCT03070730)
Timeframe: 2 weeks after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Fatigue Score on the Chalder Fatigue Questionnaire From Baseline

A 14 item self-report questionnaire. Subjects respond on a continuum of 1 to 4 questions evaluating fatigue intensity while distinguishing physical from mental fatigue. (NCT03070730)
Timeframe: 2 weeks after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Fatigue Score on the Chalder Fatigue Questionnaire From Baseline

A 14 item self-report questionnaire. Subjects respond on a continuum of 1 to 4 questions evaluating fatigue intensity while distinguishing physical from mental fatigue. (NCT03070730)
Timeframe: up to 3 days after randomization

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Heart Rate From Baseline

(NCT03070730)
Timeframe: 1 week after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Heart Rate From Baseline

(NCT03070730)
Timeframe: 1 week after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Heart Rate From Baseline

(NCT03070730)
Timeframe: 1 week after third intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Maximal Postural Tachycardia During Tilt

Maximal postural tachycardia is the maximum heart rate during a 20-min tilt table test. (NCT03070730)
Timeframe: Up to 3 days after randomization

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Muscle Sympathetic Nerve Activity From Baseline

(NCT03070730)
Timeframe: 1 week after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Muscle Sympathetic Nerve Activity From Baseline

(NCT03070730)
Timeframe: 1 week after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Muscle Sympathetic Nerve Activity From Baseline

(NCT03070730)
Timeframe: 1 week after third intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning- 7 Item Patient Global Impression of Change From Baseline

"Measures of follow up testing will be the scores on the physical functioning subscale of the 7 item patient global impression of change with items anchored by :very much better to very much worse." (NCT03070730)
Timeframe: 1 week after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning- 7 Item Patient Global Impression of Change From Baseline

"Measures of follow up testing will be the scores on the physical functioning subscale of the 7 item patient global impression of change with items anchored by :very much better to very much worse." (NCT03070730)
Timeframe: 1 week after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning- 7 Item Patient Global Impression of Change From Baseline

"Measures of follow up testing will be the scores on the physical functioning subscale of the 7 item patient global impression of change with items anchored by :very much better to very much worse." (NCT03070730)
Timeframe: 1 week after third intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning- HADS From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Hospital Anxiety and Depression Scales. (NCT03070730)
Timeframe: 1 week after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning- HADS From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Hospital Anxiety and Depression Scales. (NCT03070730)
Timeframe: 1 week after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning- HADS From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Hospital Anxiety and Depression Scales. (NCT03070730)
Timeframe: 1 week after third intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-CIS From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Checklist Individual Strength (CIS). (NCT03070730)
Timeframe: 1 week after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-CIS From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Checklist Individual Strength (CIS). (NCT03070730)
Timeframe: 1 week after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-CIS From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Checklist Individual Strength (CIS). (NCT03070730)
Timeframe: 1 week after third intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-EuroQOL From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the EuroQOL. (NCT03070730)
Timeframe: 1 week after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-EuroQOL From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the EuroQOL. (NCT03070730)
Timeframe: 1 week after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-EuroQOL From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the EuroQOL. (NCT03070730)
Timeframe: 1 week after third intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-FSS From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Fatigue Severity Scale. (NCT03070730)
Timeframe: 1 week after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-FSS From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Fatigue Severity Scale. (NCT03070730)
Timeframe: 1 week after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-FSS From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Fatigue Severity Scale. (NCT03070730)
Timeframe: 1 week after third intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-MFI From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Multidimensional Fatigue Inventory (MFI). (NCT03070730)
Timeframe: 1 week after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-MFI From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Multidimensional Fatigue Inventory (MFI). (NCT03070730)
Timeframe: 1 week after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-MFI From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Multidimensional Fatigue Inventory (MFI). (NCT03070730)
Timeframe: 1 week after third intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-OI From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Orthostatic Intolerance Questionnaire. (NCT03070730)
Timeframe: 1 week after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-OI From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Orthostatic Intolerance Questionnaire. (NCT03070730)
Timeframe: 1 week after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-OI From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Orthostatic Intolerance Questionnaire. (NCT03070730)
Timeframe: 1 week after third intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-SF-36 Q From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the SF-36 questionnaire. (NCT03070730)
Timeframe: 1 week after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-SF-36 Q From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the SF-36 questionnaire. (NCT03070730)
Timeframe: 1 week after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-SF-36 Q From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the SF-36 questionnaire. (NCT03070730)
Timeframe: 1 week after third intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Vascular Resistance From Baseline

(NCT03070730)
Timeframe: 1 week after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Vascular Resistance From Baseline

(NCT03070730)
Timeframe: 1 week after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Vascular Resistance From Baseline

(NCT03070730)
Timeframe: 1 week after third intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change Maximal Postural Tachycardia During Tilt

Maximal postural tachycardia is the maximum heart rate during a 20-min tilt table test. (NCT03070730)
Timeframe: 2 weeks after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change Maximal Postural Tachycardia During Tilt

Maximal postural tachycardia is the maximum heart rate during a 20-min tilt table test. (NCT03070730)
Timeframe: 2 weeks after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Reviews

7 reviews available for clonidine and Syndrome

ArticleYear
[Spastic syndrome and main directions of its treatment].
    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2003, Volume: 103, Issue:12

    Topics: Anti-Dyskinesia Agents; Botulinum Toxins; Clonidine; Exercise Therapy; Humans; Motor Neuron Disease;

2003
Long-term use of clonidine in a critically-ill infant.
    Paediatric anaesthesia, 2005, Volume: 15, Issue:8

    Topics: Analgesics; Clonidine; Critical Illness; Fatal Outcome; Follow-Up Studies; Hemangioma; Humans; Infan

2005
Abrupt cessation of treatment in hypertension: consideration of clinical features, mechanisms, prevention and management of the discontinuation syndrome.
    American heart journal, 1981, Volume: 102, Issue:3 Pt 1

    Topics: Acute Disease; Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Bethanidine; Blood Pressure; Cloni

1981
[Possibilities and limits of non-hormonal therapy of the menopausal syndrome].
    La Clinica terapeutica, 1984, Nov-30, Volume: 111, Issue:4

    Topics: Bromocriptine; Climacteric; Clonidine; Dopamine; Female; Gonadotropin-Releasing Hormone; Humans; Men

1984
[Clinical and endocrine diagnosis of pheochromocytoma].
    Zentralblatt fur Chirurgie, 1997, Volume: 122, Issue:6

    Topics: 3-Iodobenzylguanidine; Adrenal Gland Neoplasms; Catecholamines; Clonidine; Humans; Iodine Radioisoto

1997
[The use of sirdalud in painful muscle tonic syndromes].
    Terapevticheskii arkhiv, 1997, Volume: 69, Issue:10

    Topics: Clonidine; Humans; Muscle Relaxants, Central; Muscle Spasticity; Muscle Tonus; Muscular Diseases; Pa

1997
Thalamic hemorrhage following carotid endarterectomy-induced labile blood pressure: controlling the liability with clonidine--a case report.
    Angiology, 1999, Volume: 50, Issue:4

    Topics: Aged; Antihypertensive Agents; Baroreflex; Blood Pressure Monitoring, Ambulatory; Cerebral Hemorrhag

1999

Trials

4 trials available for clonidine and Syndrome

ArticleYear
[A role of treatment of autonomic syndrome in patients with tension-type headache].
    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2015, Volume: 115, Issue:2

    Topics: Administration, Oral; Adult; Analgesics, Non-Narcotic; Autonomic Nervous System; Autonomic Nervous S

2015
GH response to hypoglycemia and clonidine in the GH-releasing hormone resistance syndrome.
    Journal of endocrinological investigation, 2006, Volume: 29, Issue:9

    Topics: Adolescent; Adult; Blood Glucose; Body Height; Child; Child, Preschool; Clonidine; Dwarfism, Pituita

2006
Panic-induced elevation of plasma MHPG levels in phobic-anxious patients. Effects of clonidine and imipramine.
    Archives of general psychiatry, 1983, Volume: 40, Issue:4

    Topics: Adult; Anxiety Disorders; Clonidine; Double-Blind Method; Fear; Female; Glycols; Humans; Imipramine;

1983
[The treatment of the phantom pain syndrome with tizanidine].
    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 1997, Volume: 97, Issue:3

    Topics: Adult; Aged; Analgesics; Chronic Disease; Clonidine; Double-Blind Method; Female; Humans; Male; Midd

1997

Other Studies

32 other studies available for clonidine and Syndrome

ArticleYear
Use of clonidine in the treatment of Irukandji syndrome: A 4-year retrospective cohort study on safety, efficacy and clinical utility.
    Emergency medicine Australasia : EMA, 2022, Volume: 34, Issue:4

    Topics: Analgesics; Analgesics, Opioid; Bites and Stings; Clonidine; Cnidarian Venoms; Humans; Retrospective

2022
Episodic headache with spontaneous hypothermia reveal Shapiro's syndrome variant with effectiveness of clonidine therapy.
    The journal of headache and pain, 2021, Apr-26, Volume: 22, Issue:1

    Topics: Aged; Agenesis of Corpus Callosum; Clonidine; Female; Headache; Humans; Hyperhidrosis; Hypothermia;

2021
Spontaneous Osteonecrosis of the Jaw During Bisphosphonate Therapy: An Unusual Etiology of the Numb Chin Syndrome.
    Journal of pain & palliative care pharmacotherapy, 2016, Volume: 30, Issue:3

    Topics: Aged; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bupivaca

2016
Clonidine to treat Irukandji syndrome.
    Emergency medicine Australasia : EMA, 2016, Volume: 28, Issue:6

    Topics: Adrenergic alpha-2 Receptor Agonists; Analgesics; Bites and Stings; Clonidine; Cnidarian Venoms; Fem

2016
Clonidine as a sole sedative agent for MRI study in a child with Joubert syndrome.
    Paediatric anaesthesia, 2010, Volume: 20, Issue:6

    Topics: Adrenergic alpha-Agonists; Cerebellar Diseases; Child, Preschool; Clonidine; Conscious Sedation; Hum

2010
Anesthetic management in a child with Coffin-Siris syndrome.
    Paediatric anaesthesia, 2004, Volume: 14, Issue:8

    Topics: Abnormalities, Multiple; Amides; Analgesia, Epidural; Analgesics; Anesthetics, Inhalation; Anestheti

2004
Dexmedetomidine in the treatment of cyclic vomiting syndrome.
    Paediatric anaesthesia, 2005, Volume: 15, Issue:8

    Topics: Adrenergic alpha-Agonists; Bradycardia; Child; Clonidine; Dexmedetomidine; Humans; Hypnotics and Sed

2005
Stability and compatibility of a meperidine-clonidine mixture in portable pump reservoirs for the management of cancer pain syndromes.
    Journal of pain and symptom management, 2006, Volume: 32, Issue:4

    Topics: Analgesics; Analgesics, Opioid; Clonidine; Complex Mixtures; Drug Combinations; Drug Stability; Huma

2006
Adverse effects of sudden withdrawal of antihypertensive medication.
    Postgraduate medicine, 1980, Volume: 68, Issue:2

    Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Blood Pressure; Clonidine; Drug Therapy, Combi

1980
The stiff-man syndrome: new pathophysiological aspects from abnormal exteroceptive reflexes and the response to clomipramine, clonidine, and tizanidine.
    Journal of neurology, neurosurgery, and psychiatry, 1984, Volume: 47, Issue:3

    Topics: Adult; Brain Stem; Clomipramine; Clonidine; Diazepam; Electromyography; Female; Humans; Muscle Rigid

1984
[Clinidine-induced bradycardia: studies of the effect on the human sinus node (author's transl)].
    Deutsche medizinische Wochenschrift (1946), 1981, Jan-30, Volume: 106, Issue:5

    Topics: Aged; Arrhythmias, Cardiac; Bradycardia; Carotid Sinus; Clonidine; Female; Heart Rate; Humans; Male;

1981
Hormonal and metabolic effects and pharmacokinetics of recombinant insulin-like growth factor-I in growth hormone receptor deficiency/Laron syndrome.
    The Journal of clinical endocrinology and metabolism, 1993, Volume: 77, Issue:1

    Topics: Adult; Blood Glucose; Calcium; Carrier Proteins; Clonidine; Ecuador; Female; Growth Hormone; Half-Li

1993
Effect of apraclonidine hydrochloride on the attack of Posner-Schlossman syndrome.
    Korean journal of ophthalmology : KJO, 1993, Volume: 7, Issue:1

    Topics: Adolescent; Adrenergic alpha-Agonists; Adult; Aged; Clonidine; Female; Glaucoma, Open-Angle; Hemodyn

1993
A case of narcotic bowel syndrome successfully treated with clonidine.
    Postgraduate medical journal, 1994, Volume: 70, Issue:820

    Topics: Abdominal Pain; Adult; Analgesics, Opioid; Chronic Disease; Clonidine; Female; Humans; Substance Wit

1994
The stability of mixtures of morphine hydrochloride, bupivacaine hydrochloride, and clonidine hydrochloride in portable pump reservoirs for the management of chronic pain syndromes.
    Journal of pain and symptom management, 1994, Volume: 9, Issue:5

    Topics: Bupivacaine; Chronic Disease; Clonidine; Drug Combinations; Drug Stability; Humans; Infusion Pumps;

1994
Multiple lipolysis defects in the insulin resistance (metabolic) syndrome.
    The Journal of clinical investigation, 1994, Volume: 93, Issue:6

    Topics: Adipose Tissue; Aged; Clonidine; Dose-Response Relationship, Drug; Humans; Insulin Resistance; Isopr

1994
The diagnosis and treatment of baroreflex failure.
    The New England journal of medicine, 1993, Nov-11, Volume: 329, Issue:20

    Topics: Adult; Baroreflex; Blood Pressure; Catecholamines; Clonidine; Female; Humans; Hypertension; Male; Mi

1993
Clonidine side effect.
    Journal of the American Academy of Child and Adolescent Psychiatry, 1997, Volume: 36, Issue:2

    Topics: Adrenergic alpha-Agonists; Aggression; Autistic Disorder; Child; Clonidine; Depression; Humans; Male

1997
Glaucomatocyclitic crisis in a child.
    American journal of ophthalmology, 1998, Volume: 126, Issue:1

    Topics: Adolescent; Clonidine; Corneal Edema; Diagnosis, Differential; Drug Therapy, Combination; Glaucoma;

1998
When all else fails: stepwise multiple solutions for a complex cancer pain syndrome.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 1999, Volume: 7, Issue:1

    Topics: Aged; Analgesics; Analgesics, Opioid; Anesthetics, Local; Bupivacaine; Cholinesterase Inhibitors; Cl

1999
Hemodynamic and symptomatic effects of acute interventions on tilt in patients with postural tachycardia syndrome.
    Clinical autonomic research : official journal of the Clinical Autonomic Research Society, 2000, Volume: 10, Issue:1

    Topics: Adolescent; Adult; Anti-Arrhythmia Agents; Antihypertensive Agents; Clonidine; Female; Hemodynamics;

2000
Clonidine withdrawal syndrome in Tanzania--a substantial risk.
    Tropical doctor, 1978, Volume: 8, Issue:2

    Topics: Adult; Clonidine; Female; Humans; Hypertension; Long-Term Care; Male; Middle Aged; Substance Withdra

1978
Preoperative clonidine withdrawal syndrome.
    Anesthesiology, 1979, Volume: 51, Issue:1

    Topics: Antihypertensive Agents; Clonidine; Humans; Male; Middle Aged; Preoperative Care; Substance Withdraw

1979
Roberts's syndrome and clonidine.
    Journal of medical genetics, 1979, Volume: 16, Issue:6

    Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Cleft Lip; Cleft Palate; Clonidine; Diazepam;

1979
Clonidine therapy for Shapiro's syndrome.
    The Quarterly journal of medicine, 1992, Volume: 82, Issue:299

    Topics: Adult; Agenesis of Corpus Callosum; Body Temperature Regulation; Clonidine; Humans; Hyperhidrosis; H

1992
Lack of evidence for alpha-adrenergic receptor-mediated mechanisms in the genesis of ischemia in syndrome X.
    The American journal of cardiology, 1989, Aug-01, Volume: 64, Issue:5

    Topics: Adult; Angina Pectoris; Clonidine; Coronary Angiography; Coronary Disease; Electrocardiography; Exer

1989
Recurrent attacks of vomiting, hypertension and psychotic depression: a syndrome of periodic catecholamine and prostaglandin discharge.
    Acta endocrinologica, 1988, Volume: 117, Issue:2

    Topics: Adolescent; Adrenocorticotropic Hormone; Arginine Vasopressin; Child, Preschool; Clonidine; Dinopros

1988
High-dose clonidine motor syndrome: relationship to serotonin syndrome.
    Behavioural brain research, 1987, Volume: 24, Issue:3

    Topics: Adrenergic alpha-Antagonists; Animals; Behavior, Animal; Brain; Clonidine; Dose-Response Relationshi

1987
Altered norepinephrine metabolism in Shapiro's syndrome.
    Archives of neurology, 1989, Volume: 46, Issue:1

    Topics: Aged; Agenesis of Corpus Callosum; Clonidine; Female; Humans; Hypothermia; Middle Aged; Norepinephri

1989
Neuropharmacological investigations in the stiff-man syndrome.
    Journal of neurology, 1986, Volume: 233, Issue:6

    Topics: Adrenergic Fibers; Central Nervous System Diseases; Clonidine; Diazepam; Female; Humans; Methampheta

1986
Effects of clonidine on blood pressure, noradrenaline, cortisol, growth hormone, and prolactin plasma levels in high and low intestinal tone depressed patients.
    Neuroendocrinology, 1985, Volume: 41, Issue:2

    Topics: Blood Pressure; Clonidine; Depressive Disorder; Female; Gastrointestinal Motility; Growth Hormone; H

1985
[Etiology and therapy of the parotid gland syndrome].
    Munchener medizinische Wochenschrift (1950), 1973, Apr-27, Volume: 115, Issue:17

    Topics: Antihypertensive Agents; Chewing Gum; Clonidine; Dihydroxyphenylalanine; Eating; Humans; Neostigmine

1973